Atara Biotherapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa Transcript
And now, it's my pleasure to present Atara Biotherapeutics, and its CEO, Pascal Touchon.
Morning, everybody. It's a pleasure to be here today and to be here on behalf of what we call our champions, patients with cellulose disease that we are addressing at Atara that are daily fighting against their diseases. And we call them our champions because we're here to support these champions, to find solutions for them to better fight their devastating diseases.
So I'll let you first enjoy your forward-looking statements to make sure you are all clear in your mind about what we're going to discuss in a minute. But let me summarize what we're doing at Atara in saying that we're here to build an innovative, off-the-shelf, allogeneic T cell platform that is relying on Epstein-Barr virus or EBV-specific T cells that are coming from healthy donors that then we manufacture and prepare as product. And we could, in some cases, apply next-gen CAR T technologies to these cells to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
